The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564. Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries. Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments. Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer. Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more. Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC. Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data. Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC. Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation. Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024. Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer. Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
... The Uromigos discuss the presentations to look out for at this year's ASCO Genitourinary Cancers Symposium. Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature. Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer. Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024. Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April. Cristina Suarez discusses the biggest RCC trials of 2023. Elena Castro, Begoña Valerrama and Cristina Suárez analyze some of the urothelial carcinoma research highlights of 2023. The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.